Kynurenine pathway metabolism and neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy

Show simple item record

dc.contributor.author Allen, Andrew P.
dc.contributor.author Naughton, M.
dc.contributor.author Dowling, J.
dc.contributor.author Walsh, A.
dc.contributor.author O'Shea, R.
dc.contributor.author Shorten, George D.
dc.contributor.author Scott, Lucinda V.
dc.contributor.author McLoughlin, D. M.
dc.contributor.author Cryan, John F.
dc.contributor.author Clarke, Gerard
dc.contributor.author Dinan, Timothy G.
dc.date.accessioned 2018-02-13T11:59:13Z
dc.date.available 2018-02-13T11:59:13Z
dc.date.issued 2018-02-10
dc.identifier.citation Allen, A. P., Naughton, M., Dowling, J., Walsh, A., O'Shea, R., Shorten, G., Scott, L., McLoughlin, D. M., Cryan, J. F., Clarke, G. and Dinan, T. D. (2018) 'Kynurenine pathway metabolism and neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy', Journal of Psychiatric Research, In Press. doi: 10.1016/j.jpsychires.2018.02.011 en
dc.identifier.startpage 1 en
dc.identifier.endpage 39 en
dc.identifier.issn 0022-3956
dc.identifier.uri http://hdl.handle.net/10468/5449
dc.identifier.doi 10.1016/j.jpsychires.2018.02.011
dc.description.abstract Current first-line antidepressants can take weeks or months to decrease depressive symptoms. Low dose ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows potential for a more rapid antidepressant effect, with efficacy also evident in previously treatment-resistant populations. However, a greater understanding of the physiological mechanisms underlying such effects is required. We assessed the potential impact of ketamine infusion on neurobiological drivers of kynurenine pathway metabolism in major depression (HPA axis hyperactivity, inflammation) in patients with treatment-resistant depression compared to gender-matched healthy controls. Furthermore, we assessed these biomarkers before and after electroconvulsive therapy (ECT), which is currently the gold standard for management of treatment-resistant depression. As previously demonstrated, treatment with ketamine and ECT was associated with improved depressive symptoms in patients. At baseline, waking cortisol output was greater in the ECT cohort, kynurenine was greater in the ketamine cohort, and kynurenic acid was less in patients compared to healthy controls, although inflammatory markers (IL-6, IL-8, IL-10 or IFN-γ) were similar in patients and controls. Furthermore, in patients who responded to ECT, the cortisol awakening response was decreased following treatment. Despite a trend towards lesser kynurenine concentrations in those who responded to ketamine, ketamine was not associated with significant alterations in any of the biomarkers assessed. en
dc.description.sponsorship Science Foundation Ireland (SFI through the Irish Government's National Development Plan); Health Research Board (grants no HRA_POR/2011/23, HRA_POR/2012/32, HRA-POR-2-14-647); Brain and Behavior Research Foundation (NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation (Grant Number 20771) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier en
dc.relation.uri https://www.sciencedirect.com/science/article/pii/S0022395617310877
dc.rights © 2018 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. en
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ en
dc.subject Depression en
dc.subject Ketamine en
dc.subject Cortisol en
dc.subject Immune en
dc.subject Cytokine en
dc.subject Kynurenine en
dc.title Kynurenine pathway metabolism and neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Ted Dinan, Psychiatry, University College Cork, Cork, Ireland. +353-21-490-3000 Email: t.dinan@ucc.ie en
dc.internal.availability Full text available en
dc.check.info Access to this article is restricted until 12 months after publication by request of the publisher. en
dc.check.date 2019-02-10
dc.date.updated 2018-02-13T11:27:18Z
dc.description.version Accepted Version en
dc.internal.rssid 425602909
dc.contributor.funder Science Foundation Ireland en
dc.contributor.funder Health Research Board en
dc.contributor.funder European Commission en
dc.contributor.funder Seventh Framework Programme en
dc.contributor.funder Brain and Behavior Research Foundation en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Journal of Psychiatric Research en
dc.internal.copyrightchecked No !!CORA!! en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress t.dinan@ucc.ie en
dc.internal.bibliocheck In Press, February 2018. Update citation details, page numbers, add volume, issue en
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2273/IE/Alimentary Pharmabiotic Centre (APC) - Interfacing Food & Medicine/ en
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP1::KBBE/613979/EU/Microbiome Influence on Energy balance and Brain Development-Function Put into Action to Tackle Diet-related Diseases and Behavior./MYNEWGUT en
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/201714/EU/Serotonin and GABA-B receptors in anxiety : from developmental risk factors to treatment./DEVANX en


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2018 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. Except where otherwise noted, this item's license is described as © 2018 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement